利伐沙班治疗静脉血栓吗

(Rivaroxaban) is a new oral anticoagulant that can highly selectively and directly inhibit bound or free factor

A domestic study compared 32 patients each in the rivaroxaban group and the warfarin group. The results showed that the total effective rate of treatment in the rivaroxaban group was 96.88%, which was higher than the warfarin group; the incidence of adverse reactions in the rivaroxaban group was 3.13%, which was lower than the warfarin group. These results indicate that rivaroxaban has similar efficacy to standard treatment, but with fewer major bleeding events and less intracranial bleeding in critical areas than the standard treatment group.

In addition, some researchers included 80 patients with venous thromboembolism in the study. The results showed that rivaroxaban has a significant effect in the treatment of patients with venous thromboembolism (P<0.05). It will not inhibit the patient's coagulation function, nor will it have a major impact on the patient's cardiac function. It is highly safe and worthy of recommendation.

There is also a domestic study of 35 patients with pulmonary embolism. The conventional group (n=18) was treated with warfarin, and the observation group (n=17) was treated with rivaroxaban. After the two groups were treated, the treatment effect of the patients in the observation group was better than that of the conventional group, and the incidence of adverse reactions was lower than that of the conventional group.

Another researcher divided 93 patients with lower extremity deep vein thrombosis into groups. 43 patients in group A were treated with warfarin, and 50 patients in group B were treated with rivaroxaban. The total effective rate after treatment in group B was higher than that in group A. The improvements in above-knee difference, below-knee difference, venous blood flow velocity, and various coagulation function indicators in group B were better than those in group A. As a single drug, rivaroxaban can effectively treat DVT and PE, reduce the occurrence of adverse reactions, and is worthy of clinical application.

It can be seen that (Xarelto) can be used to treat venous thrombosis, and the therapeutic effect is obvious.

Recommended hot articles: /newsDetail/73284.html